The molecular processes underlying the ageing-related decline in cognitive performance and 25 memory observed in humans are poorly understood. Studies in rodents have shown that N-26 methyl-D-aspartate receptors (NMDARs) containing GluN2B subunits can enhance the ability of 27 synapses to undergo long term potentiation. In ageing rodents, the contribution of GluN2B to 28 synaptic function is reduced compared to younger animals and the decline in GluN2B subunit 29 expression is correlated with impaired memory functions. However, the contribution of GluN2B 30 containing receptors to synaptic transmission in cortical synapses has not been previously studied. 31
Introduction 43
Glutamate is the neurotransmitter of cortical and hippocampal pyramidal neurons and thus is a 44 mediator cognitive functions. Glutamate-gated receptors of the NMDA subtype require 45 intracellular depolarisation to relieve voltage-dependent extracellular Mg 2+ block of the ion 46 channel pore. Once opened, NMDAR channels can allow Ca 2+ influx which triggers the synaptic 47 life (Jantzie et al., 2013) . Importantly, GluN2B has been found to co-assemble with PSD-95 in 72 resected brain tissue from patients <17 years old (Ying et al., 2004) , suggesting that GluN2B 73 might contribute to synaptic transmission in young adult cortical synapses. However, it is 74 unknown whether there is further reduction of GluN2B in adulthood or old age and whether 75
GluN2B-containing NMDAR contribute to synaptic transmission in the adult brain. 76 77 Here, we tested directly whether GluN2B-containing NMDARs contribute to synaptic function in 78 adult human cortical neurons. We used non-pathological tissue resected during neurosurgery 79 from patients to test for NMDAR subunit composition in tissue homogenates and their 80 association with the major synaptic scaffolding protein PSD-95. Furthermore we analysed 81 synaptic transmission using patch clamp electrophysiology in brain slices of live temporal cortex. 82
Our results show that NMDA/AMPA ratio decreases with age with a marked decline of GluN2B-83 NMDAR current in older synapses. 84 85 Materials and Methods 86
Tissue Collection 87
The use of human tissue complied with the Human Tissue Act (Southampton Research 88
Biorepository study reference number: SRB002/14). Informed consent was obtained from all 89 patients to use surgically-resected tissue not required for diagnostic purposes. Temporal cortex 90 was chosen as its availability was sufficient to allow statistical analysis of data. Human brain slices 91 were prepared as previously described by Verhoog et al. (2013) . Briefly, resected tissue was 92 obtained from temporal cortex of patients undergoing surgery for the removal of deeper 93 structures. We obtained temporal cortical tissue from 17 individual neurosurgery cases (Table 1) of AMPAR and NMDAR-mediated currents to individual EPSCs, the holding membrane potential 154 was clamped at −70mV and +40mV, respectively, in alternating sweeps. Cells were maintained at 155 −70 mV in between stimuli and the membrane potential was changed to holding potential 2 sec 156 prior to synaptic stimulation. Evoked EPSCs were analysed using custom-written MATLAB scripts. 157
A minimum of 5 continuously recorded sweeps for each AMPAR and NMDAR were measured. 158 AMPAR current was measured at its peak and NMDAR current was measured as the average 159 current at 55-57ms following stimulation, at which time the AMPAR showed decay to ~5% of its 160 peak amplitude. The NMDAR/AMPAR ratio was calculated by dividing the amplitude of NMDAR 161 current measured by the peak AMPAR current. Successful patch clamp recordings in whole-cell 162 configuration could be made up until 12 hours after resection using this tissue. 163
164
Averaged evoked NMDAR currents (from peak back to baseline) were fitted with least squares 165 Labs). Sections were then incubated in the avidin-biotinylated horseradish peroxidase complex 212 (ABC) for 30 minutes. Following the ABC incubation sections were mounted onto gelatinised slides 213 and were developed using 3,3'-diaminobenzidine (DAB) precipitation. Sections were washed (3 x 214 5min) in 0.1M PB, dehydrated using increasing ethanol percentages (70%, 80%, 95% and 2x100%, 215
for 5 minutes each). Sections were incubated in xylene (2x10minutes each) and mounted using 216
Entellan® New, mounting medium. Images from stained sections were taken using a Leica 217
Microscope (Leica DM5000B) with Q software for image capture. 
Results 246
We used non-pathological cortical tissue samples resected during neurosurgical procedures to 247 obtain access to deep brain lesions ( Fig. 1A , Table 1 ). The tissue was collected in theatre and 248 rapidly processed using the brain slice technique (Verhoog et al. 2013 ). The well-preserved cortical 249 architecture of these slices (Fig. 1B ) allowed for electrophysiological recordings in putative LII-III 250 pyramidal neurons that were identified by their location within cortical layers and their 251 morphology (Fig. 1C ). First, we characterised the quality and health of collected tissues using fixed 252 or snap-frozen samples of brain tissue that were immediately adjacent to that used for 253 electrophysiology. Reactive astrocytes and activated microglia are reliable inflammatory indicators 254 of disease in mammalian brain tissue (Perry et al. 2010) ( Figure 1D ). As positive controls for 255 inflammatory pathology, we stained pathological sections (epileptic foci N = 2 patients, tumour 256 tissue N = 1 or cavernous malformation tissue N = 1) with GFAP to label astrocytes and Iba1 to 257 label microglia. We compared putative non-pathological tissue ( Supplementary Fig. 1A -E) against 258 pathological tissue (cases 11 and 21). Qualitatively, the putative non-pathological tissue showed 259 normal GFAP-positive cell morphology in contrast with highly ramified and fibrotic astrocytes 260 observed in pathological tissue. Furthermore, the GFAP density was significantly lower in putative 261 non-pathological tissue than in pathological tissue. In our Iba1 analyses, we found two cases with 262 activated microglia density similar to that of positive controls ( Fig. 1D and Suppl. Fig. 1C ). We 263 therefore labelled these two cases as observed pathology (OP) and excluded them from synaptic 264 analyses. The density of microglia in the human brain does not change with age, as recently 265 reported by us (Askew et al., 2017). Here, we observed densities in accordance with previously 266 published data, and similarly did not observe significant age-dependent changes in astrocyte 267 density (r = -0.03 p = 0.92) or microglia density (r = -0.54 p = 0.09). 268 269 Next, we sought to further control for resected tissue quality by measuring the ratio of full length 270 to cleaved GluN2B protein, which has previously been demonstrated as a robust control for 271 synaptic proteome integrity in post-mortem human brain tissue (Bayés et al., 2014) . Using 272
Western blot analysis of GluN2B in fresh frozen samples with an antibody that recognises full-273 length protein (Band 1, 180kDa) and cleaved products (Bands 2 and 3, 150 and 115kDa), we 274 measured the ratio of full-length to cleaved GluN2B ( Figure 1E Figure 1F-G) . We observed a similar GluN2B protein profile in rapidly 281 processed adult mouse brain tissue ( Fig 1E-G) , which confirmed that basal cleavage of GluN2B in 282 fresh frozen tissue was not an artefact of tissue collection. This shows that high quality tissue can 283 be obtained from human patients irrespective of age. 284
285
To test whether total protein levels decrease with age, we performed further Western blot 286 quantifications of GluN2A and GluN2B subunits. We found that both GluN2A and GluN2B protein 287 levels decreased with age, and a trend (p = 0.08) was observed for GluN2A-S (Fig 2A-D) . Using PSD-288 95 pull-down from brain homogenates we were able to observe both GluN2A and GluN2B in 289 samples from 27, 49 and 50 year old patients, however in a sample from a 58 year old we were 290 not able to see GluN2B co-immunoprecipitated with PSD-95 ( Fig 2E) . Not all samples yielded 291 successful precipitated PSD-95 lanes and thus we did not quantify co-precipitation. To analyse 292 whether the observed decrease in GluN2A and GluN2B NMDAR subunits was associated with 293 overall reduction in synaptic proteins we also tested available samples for synapsin (pre-synaptic), 294 PSD-95 (post-synaptic) and the AMPAR subunit GluA1 ( Fig 3A) . We observed that there was no 295 correlation with age in the amount of these proteins in cortical homogenate normalised against 296 total protein load ( Fig 3B-G 
PSD-95
Ponceau not quantified. 321
We next analysed patch clamp recordings to determine whether these receptors participate in 322 basal synaptic transmission. NMDA and AMPA currents exhibited current voltage relationships 323 similar to those observed in rodents ( Figure 4A-B) . We analysed the age-dependence of 324 Figure 4C ), suggesting an age-dependent reduced contribution of 330
NMDARs to synaptic transmission. In contrast, the NMDA/AMPA ratio remained constant across 331 ages in recordings from slices pre-incubated with Ro 25-6981 ( Figure 4D ), which at 500 nM inhibits 332 recombinant NMDAR di-heteromers (GluN1/GluN2B). This suggests that GluN2B loss could be a 333 key determinant of reduced synaptic NMDAR input to ageing temporal cortical synapses. 334
In a subset of experiments, NMDAR currents were measured before and after application of Ro 335 25-6981 in the same cell. These experiments required holding neurons in whole-cell configuration 336 for >30 minutes to allow time for initial dialysis of intracellular voltage-clamp solution, acquisition 337 of control data, wash in of bath-applied Ro and, importantly, to allow time for full NMDAR current 338 inhibition by the use-dependent antagonist Ro 25-6981 (Fischer et al, 1997). We observed that 339 NMDA/AMPA ratios from subjects younger than 45 showed sensitivity to Ro treatment while those 340 for older than 45 subjects did not (<45 years old NMDA/AMPA ratio before = 0.88 ± 0.20, after Ro 341 25-6981 treatment = 0.46 ± 0.05 N = 3, and >45 years old NMDA/AMPA ratio before = 0.53 ± 0.15 342 after Ro 25-6981 treatment 0.474 ± 0.08, p < 0.05, N = 5). These data also show that the fraction 343 of NMDAR current inhibited by Ro was larger in synapses from younger individuals (42% ± 0.15 versus 1% ± 0.16 in older individuals, p < 0.05). These findings are consistent with our results above 345 using Ro preincubation. 346
347
Given that recombinant NMDARs containing either GluN1/GluN2A and GluN1/GluN2B have 348 distinct postsynaptic current decay kinetics (Stocca and Vicini, 1998) , we fitted a double 349 exponential decay function to all recorded currents and obtained a weighted time constant value 350 (tw, see methods) for each case. We found that tw decreased significantly with age, this is 351 consistent with synapses from younger individuals having a higher proportion of synaptic GluN2B 352 containing receptors that is progressively reduced with age ( Fig 4E) . Interestingly, we found that 353
in the presence of Ro 25-6981 500 nM there was still significant decrease of tw with age albeit at 354 lower significance value (p< 0.05) and with a smaller correlation coefficient than in the absence of 355
Ro 25-6981 (r = -0.57). It is possible that tri-heteromers, that have tw larger than GluN1/GluN2A 356 but lower than GluN1/GluN2B di-heteromers are the cause of this enhanced tw in younger 357 individuals. In this instance, Ro 25-6981 (an ifenprodil derivative) would only achieve partial 358 inhibition of tri-heteromers even at saturating antagonist concentrations (Stroebel et al. 2018) . 359
However, we cannot rule out whether other slower-decaying NMDAR variants (GluN2C or GluN2D 360 or those containing GluN1 with exon5 spliced) are present at a younger age in human cortical 361 synapses. 362 2009). However, it was not known whether age dependent changes in GluN2B synaptic 416 composition also occurred over the adult human lifespan. To analyse the age dependence of 417 NMDAR composition in human synapses we studied samples from adult patients within a broad 418 age span. Using GFAP and Iba1 as inflammation markers and GluN2B as a protein degradation 419 marker, we were able to assess the quality of this tissue as non-pathological. We observed that 420 although protein expression for both glutamate receptor subunits GluN2A and GluN2B is reduced 421 with age, both proteins are still produced at detectable levels in older adults (Fig 2) . By using a 422 pharmacological approach, whereby Ro 25-6981 500 nM selectively inhibits receptors containing 423 GluN1/GluN2B subunits, our data demonstrate that a significant fraction of these NMDAR 424 channels participate in basal synaptic function in cortical slices in younger adults but less so in 425 older adults. This result is in sharp contrast with predictions from equivalent mouse studies, and 426 our own analyses where Ro 25-6981 had no significant effect of the NMDA/AMPA ratio in young 427 adult mice (3-5 months) ( Supplementary Figure 2 
